A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Inavolisib
DRUG: Phesgo
DRUG: Placebo
DRUG: Taxane-based Chemotherapy
DRUG: Optional Endocrine Therapy of Investigator's Choice

Sponsor

Hoffmann-La Roche